The cannabis industry hit a possible milestone in March when Bright Green Corp., a Florida company with “conditional” approval from the U.S. Drug Enforcement Administration to grow marijuana for research purposes, applied to list on the Nasdaq stock exchange.
But the move also highlights the lofty – some say unrealistic – financial ambitions of such companies.
Can DEA-backed cannabis growers strike gold via drug development?
PUBLISHED Apr 20, 2022
Mar 04, 2022
How will Groff North America cannabis products be developed from research to market as medicines?
How will Groff North America cannabis products be developed from research to market as medicines? CEO Joe Gryzb talked to Harri Leigh of WPMT FOX43 about the potenti Read more
Mar 03, 2022
We are making history at Groff North America!
We are making history at Groff North America. After 53 years, we are one of five companies approved to grow and study cannabis for medical research in the U.S. WPMT Read more
Mar 02, 2022
The transition from medical marijuana to cannabis-based pharmaceutical drugs | Little Green Pill
We know cannabis has powerful potential medical effects. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field Read more
Feb 23, 2022
Groff North America makes historic cannabis transaction with DEA
FOR IMMEDIATE RELEASE CONTACT: Jay Scott email@example.com 484-695-3774 Groff North America makes historic cannabis transactio Read more